All News AstraZeneca PLC

Equities

AZN

GB0009895292

Market Closed - London S.E. Other stock markets 11:35:23 2024-05-03 am EDT			5-day change	1st Jan Change
12,050 ^GBX	-0.87%		+0.52%	+13.68%

01:18pm	Angle shares up on assay development deal with AstraZeneca	AN
12:52pm	Angle shares up on assay development deal with AstraZenaca	AN

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AI Startup Fileread Names Former AstraZeneca Legal Leader as Chief Strategy Officer and General Counsel to Drive Product Development and Accelerate Growth	09:01am	AQ
Angle shares up on assay development deal with AstraZeneca	07:18am	AN
Astrazeneca - CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial	06:59am	AQ
Angle shares up on assay development deal with AstraZenaca	06:52am	AN
Angle Plc to Supply Prostate Cancer Androgen Receptor Detection Assay to AstraZeneca	06:34am	MT
AIM WINNERS & LOSERS: Fletcher King optimistic; Angle in Astra deal	05:54am	AN
Confident start before US jobs data	03:50am	AN
InterContinental Hotels makes first-quarter progress	02:52am	AN
AstraZeneca Says Calquence Combination Improves Progression-Free Survival in Phase 3 Mantle Cell Lymphoma Trial	May. 02	MT
AstraZeneca: research into respiratory diseases	May. 02	CF
AstraZeneca : Calquence combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial - Form 6-K	May. 02	PU
CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial	May. 02	BU
AstraZeneca Announces Positive High-Level Results from an Interim Analysis of the Echo Phase III Trial	May. 02	CI
AstraZeneca PLC Announces Positive High-Level Results from an Interim Analysis of the Echo Phase III Trial	May. 02	CI
AstraZeneca: encouraging results in lymphoma	May. 02	CF
AstraZeneca notes positive trial results for Calquence treatment	May. 02	AN
AstraZeneca's Blood Cancer Combo Extends Progression-free Survival in Late-stage Study	May. 02	MT
Ipsen: new President for North America	May. 02	CF
AstraZeneca PLC Announces Calquence combination improved PFS in 1L MCL	May. 02	CI
Astrazeneca Joins Hands With Partners to Tackle Kenya's Cancer Burden	May. 01	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm EDT